MRI and PET Scan Using 18F-Fluoromisonidazole In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme



Status:Active, not recruiting
Conditions:Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/24/2018
Start Date:August 24, 2009

Use our guide to learn which trials are right for you!

Multicenter, Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) With PET and MRI

This phase II trial is studying how well positron emission tomography (PET) scan using
18F-fluoromisonidazole works when given together with magnetic resonance imaging (MRI) ) in
assessing tumor hypoxia in patients with newly diagnosed glioblastoma multiforme (GBM).
Diagnostic procedures, such as MRI and PET scan using 18F-fluoromisonidazole (FMISO), may
help predict the response of the tumor to the treatment and allow doctors to plan better
treatment.

PRIMARY OBJECTIVES:

I. To determine the association of baseline FMISO PET uptake (hypoxic volume [HV]), highest
tumor:blood ratio [T/Bmax]) and MRI parameters (Ktrans, CBV) with overall survival (OS) in
participants with newly diagnosed GBM.

SECONDARY OBJECTIVES:

I. To determine the association of baseline FMISO PET uptake (HV, T/Bmax) and MRI parameters
(Ktrans, CBV) with time to progression (TTP) and 6-month progression free survival (PFS-6) in
participants with newly diagnosed GBM.

II. To assess the reproducibility of the baseline FMISO PET uptake parameters by implementing
baseline "test" and "retest" PET scans (performed within 1 to 7 days of each other).

III. To assess the correlation between highest tissue:cerebellum ratio [T/Cmax] and T/Bmax at
baseline.

IV. To assess the correlation between other MRI parameters (T1Gd, VCI, CBV-S, ADC, NAA-Cho,
BOLD, T2) and OS, TTP, and PFS-6.

OUTLINE: This is a multicenter study.

Two weeks before initiation of chemoradiotherapy with temozolomide, patients undergo MRI and
PET scan using FMISO. A subset of 15 patients undergo FMISO PET scans approximately 1 week
before chemoradiotherapy. Blood samples are collected at baseline and periodically during
study to compare image measures of tissue uptake of FMISO to blood concentrations. Tumor
samples are collected from diagnostic biopsy or surgery for analysis of tumor hypoxic markers
and methylguanine methyl transferase by immunohistochemical and PCR assays.

After completion of study therapy, patients are followed up every 3 months for up to 5 years.

Inclusion Criteria:

- Must be able to provide a written informed consent

- Newly diagnosed GBM, World Health Organization (WHO) grade IV based on pathology
confirmation

- Residual tumor after surgery (amount of residual tumor will not impact patient
eligibility and visible residual disease can include T2/FLAIR hyperintensity)

- NOTE: If patient had a biopsy only, postoperative MRI is not needed to assess
residual tumor prior to enrollment

- Scheduled to receive standard fractionated radiation therapy

- Scheduled to receive TMZ in addition to radiation therapy

- Karnofsky Performance Score > 60

Exclusion Criteria:

- Pregnant or breastfeeding (if a female is of child-bearing potential, and unsure of
pregnancy status, a standard urine pregnancy test should be done)

- Scheduled to receive chemotherapy, immunotherapy, or investigational agents in trials
unwilling to share data with ACRIN (i.e., additional therapy added to radiation and
TMZ is allowed if ACRIN is able to obtain treatment information)

- Not suitable to undergo MRI or use the contrast agent Gd because of:

- Claustrophobia

- Presence of metallic objects or implanted medical devices in body (i.e., cardiac
pacemaker, aneurysm clips, surgical clips, prostheses, artificial hearts, valves with
steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants)

- Sickle cell disease

- Renal failure

- Reduced renal function, as determined by GFR < 30 mL/min/1.73 m^2 based on a serum
creatinine level obtained within 28 days prior to registration

- Presence of any other co-existing condition which, in the judgment of the
investigator, might increase the risk to the subject

- Presence of serious systemic illness, including: uncontrolled intercurrent infection,
uncontrolled malignancy, significant renal disease, or psychiatric/social situations
which might impact the survival endpoint of the study or limit compliance with study
requirements

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to FMISO; an allergic reaction to nitroimidazoles is highly unlikely

- Not suitable to undergo PET or MRI, including weight greater than 350 lbs (the weight
limit for the MRI and PET table)

- Prior treatment with implanted radiotherapy or chemotherapy sources such as wafers of
polifeprosan 20 with carmustine
We found this trial at
14
sites
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
(617) 724-4000
Massachusetts General Hospital Cancer Center An integral part of one of the world
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19103
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
1959 NE Pacific St
Seattle, Washington 98195
(206) 598-3300
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tampa, Florida 33612
?
mi
from
Tampa, FL
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
336-716-2011
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials